P&T Motion History Targeted Immune Modulators (TIMs)

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
abatacept	TIMs for Plaque Psoriasis, Psoriatic Arthritis, and	April, 17	NA	No	Passed
adalimumab	Generalized Pustular Psoriasis	2024			unanimous
anakinra*					
apremilast	After considering the evidence of safety, efficacy,				
baricitinib*	effectiveness and special populations for the use of				
bimekizumab	targeted immune modulators for their FDA approved				
brodalumab	indications relative to Plaque Psoriasis, Psoriatic				
certolizumab pegol	Arthritis, and Generalized Pustular Psoriasis. I move				
deucravacitinib	that: abatacept, adalimumab, apremilast,				
etanercept	bimekizumab, brodalumab, certolizumab pegol,				
golimumab	deucravacitinib, etanercept, golimumab, guselkumab,				
guselkumab	infliximab, ixekizumab, risankizumab, roflumilast,				
infliximab	secukinumab, spesolimab, tildrakizumab, tofacitinib,				
ixekizumab	upadacitinib, and ustekinumab are efficacious for				
natalizumab*	their approved indications, including their applicable				
ozanimod*	biosimilars when available. The PDL must include a				
risankizumab	drug approved for treatment of the following FDA				
rituximab*	indications (Plaque Psoriasis, Psoriatic Arthritis, and				
roflumilast	Generalized Pustular Psoriasis) and must include a				
sarilumab*	self-administered agent if indicated.				
secukinumab					
spesolimab	These medications cannot be subject to therapeutic				
tildrakizumab	interchange in the Washington preferred drug list.				
tocilizumab*					
tofacitinib	Motion: Flynn				
upadacitinib	2 nd : Beste				
ustekinumab					

Bold = new this update

Grey= not reviewed

^{*=}drugs not reviewed, but carried forward from previous review

P&T Motion History Targeted Immune Modulators (TIMs)

vedolizumab*					
abatacept	TIMs for Crohn Disease and Ulcerative Colitis	June 21,	RA & AP	No	Passed
adalimumab	and Rheumatoid Arthritis and Ankylosing	2023	Chawla		unanimous
anakinra	Spondylitis		Davydow		
apremilast			accepted		
baricitinib	After considering the evidence of safety, efficacy,				
brodalumab	effectiveness and special populations for the use of				
certolizumab pegol	targeted immune modulators for their FDA approved				
etanercept	indications relative to rheumatoid arthritis,				
golimumab	ankylosing spondylitis, Crohn Disease and Ulcerative				
guselkumab	Colitis. I move that: abatacept, adalimumab,				
infliximab	anakinra, baricitinib, certolizumab pegol, etanercept,				
ixekizumab	golimumab, infliximab, natalizumab, ozanimod,				
natalizumab	Risankizumab, rituximab, sarilumab, secukinumab,				
ozanimod	tocilizumab, tofacitinib, upadacitinib, ustekinumab,				
risankizumab	vedolizumab are efficacious for their approved				
rituximab	indications, including their applicable biosimilars				
sarilumab	when available. The PDL must include a drug				
secukinumab	approved for treatment of the following FDA				
tildrakizumab	indications (rheumatoid arthritis, ankylosing				
tocilizumab	spondylitis, Crohn Disease and Ulcerative Colitis)				
tofacitinib	and must include a self-administered agent if				
upadacitinib	indicated.				
ustekinumab					
vedolizumab	These medications cannot be subject to therapeutic				
	interchange in the Washington preferred drug list.				
	Motion: Beste				

Bold = new this update

Grey= not reviewed

^{*=}drugs not reviewed, but carried forward from previous review 4/25/2024

P&T Motion History Targeted Immune Modulators (TIMs)

2 nd : Weiland		